Author:
Kumar Amber,Dhingra Bhavna
Publisher
Springer Nature Singapore
Reference17 articles.
1. Comstock GW, Cauthen GM. In: Reichman LB, Hershfield ES, editors. Tuberculosis. A comprehensive international approach, vol. 66. New York: Marcel Dekker; 1993. p. 23–48.
2. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumour necrosis factor inhibitor. Clin Infect Dis. 2004;39:295–9.
3. Centres for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor- alpha – California, 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–6.
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.
5. Okur E, Yilmaz A, Saygi A, et al. Patterns of delays in diagnosis amongst patients with smear-positive pulmonary tuberculosis at a teaching hospital in Turkey. Clin Microbiol Infect. 2006;12:90–2.